Glossary
Tirzepatide
Updated March 29, 2026
Tirzepatide is a dual GIP/GLP-1 receptor agonist that activates two hormone pathways involved in appetite regulation and blood sugar control. In the SURMOUNT trials, tirzepatide produced the strongest weight loss results of any approved medication in this class (up to 22.5% body weight over 72 weeks at the 15mg dose). For people who train, this means more aggressive appetite suppression that makes deficit adherence easy but under-fueling dangerously easy too. Protein and training structure matter even more on tirzepatide than on single-receptor GLP-1 medications. For the dedicated protocol, read How to Preserve Muscle on GLP-1 Medications. For the semaglutide versus retatrutide comparison that covers the stricter protein and rate-of-loss guardrails used at the higher-suppression end of the category, read Protein Targets and Training Strategy on Semaglutide or Retatrutide. Tirzepatide also has one of the clearest withdrawal signals in the literature. In SURMOUNT-4, participants switched to placebo regained substantial weight, so coming off the drug should be treated as an active maintenance phase. The full discontinuation plan is in How to Stop GLP-1s Without Rapid Fat Regain.
Brand map
| Brand | Form | Dosing rhythm | Titration range | Physique-relevant positioning |
|---|
| Zepbound | injection | weekly | 2.5mg to 15mg over 4+ months | weight-management approved, designed for fat-loss outcomes |
| Mounjaro | injection | weekly | 2.5mg to 15mg over 4+ months | diabetes-focused, where weight loss is a secondary effect |
Physique-first planning model
| Goal | What to emphasize | Specific targets | What to avoid |
|---|
| Fat loss with muscle retention | moderate deficit, stable protein, consistent lifting | 15-25% deficit (300-500 cal/day), 1.4-1.6 g/kg protein (higher end due to stronger suppression), 3-4 lifting sessions per week | rapid loss that collapses training output (more than 1.5 lb per week consistently) |
| High-output training phase | protect carbs around sessions and keep hydration stable | pre-workout carbs 30-50g, match fluids to sweat rate (16-20 oz per hour), total intake near maintenance | using appetite suppression as a reason to skip recovery meals |
| Maintenance or recomposition | stable weekly intake with high protein | maintenance calories, 1.4-1.6 g/kg protein, track 14-day weight trends | chasing scale changes week to week |
Nutrition levers that matter most
| Lever | Specific target | Practical examples | Expected signal |
|---|
| Protein floor | 1.4-1.6 g/kg daily, 30-40g per meal (higher floor than single GLP-1 drugs due to stronger appetite suppression) | 5 oz chicken breast (~44g), 6 oz salmon (~34g), 1 cup cottage cheese (~28g), protein shake + 1 cup Greek yogurt (~45g) | strength holds while weight trends down |
| Carbohydrate placement | move carbs toward training windows, especially on low-appetite days | 30-50g carbs pre-workout (oatmeal, banana, rice), 20-40g post-workout (rice, fruit, potato) | better session quality and fewer late-night cravings |
| Hydration + electrolytes | 64-80 oz daily, plus 16-20 oz per hour of training, pair with sodium on heavy sweat days | 32 oz bottle x2 before dinner, add a pinch of salt or electrolyte tab during long sessions | fewer headaches and less dizziness |
| Fiber ramp | 25-30g daily, increase slowly (3-5g per week) | 1/2 cup lentils (~8g), 1 cup broccoli (~5g), 1 oz chia seeds (~10g) | better digestion without GI backlash from jumping too fast |
Training integration on tirzepatide
| Training context | Pre-workout nutrition (60-90 min before) | Post-workout nutrition (within 2 hours) | Adjustment cues |
|---|
| Standard session | 30-40g carbs + 20g protein (oatmeal + protein shake, banana + Greek yogurt) | 35-40g protein + 30-40g carbs (chicken + rice + vegetables) | if sessions feel flat for 2+ workouts, increase pre-workout carbs by 15-20g |
| Low-appetite day | minimum 20g carbs (rice cake + honey, half banana) | 30g protein in any tolerable format (shake, yogurt, deli meat) | reduce training volume by 1-2 sets rather than skipping |
| High-output session (legs, back) | 40-50g carbs + 20-25g protein, 90 min before | 40-50g protein + 40-50g carbs within 90 min | these are the highest-risk sessions for under-fueling on tirzepatide |
| Dose increase week | keep meals smaller and blander for 3-7 days until GI tolerance stabilizes | prioritize protein (25-30g minimum) even if total calories are below normal | nausea and fullness spike after dose increases, reduce meal size and increase frequency |
Body composition monitoring
Tirzepatide's stronger appetite suppression means weight can drop fast, which makes distinguishing fat loss from muscle loss especially important. Use 14-day trend windows and multiple signals.
| What to track | How to measure | Frequency | Decision rule |
|---|
| Weight trend | morning weigh-in under same conditions, 14-day rolling average | daily weigh-in, weekly trend review | losing more than 1.5 lb per week consistently warrants intake audit |
| Waist and hip circumference | fabric tape at navel and widest hip point | every 2 weeks | waist dropping while weight is stable suggests recomposition |
| Strength in core lifts | track top sets in squat, bench, row, or deadlift | every session | strength dropping across 2+ weeks means under-fueling first, not training programming |
| Limb circumference | mid-bicep and mid-thigh with fabric tape | monthly | large drops alongside rapid weight loss suggest lean mass loss |
| Progress photos | same lighting, time of day, and poses | monthly | visual check that complements the numbers |
Safety and escalation thresholds
| Signal pattern | Why it matters | Next step |
|---|
| Severe abdominal pain with persistent vomiting | pancreatitis or gallbladder complication risk | urgent clinical evaluation |
| Persistent dehydration signs or inability to keep fluids down | kidney and electrolyte stress risk | seek medical guidance and stabilize hydration |
| Severe weakness or confusion, especially in a diabetes-medication stack | systemic or glucose risk | urgent evaluation |